myeloma
No description yet: the sentence for this tag has not been written. 14 records carry it: 14 people.
Related tags
14 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Ajai Chari Director of the Multiple Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center · UCSF Helen Diller Family Comprehensive Cancer Center Led the pivotal talquetamab trial, establishing GPRC5D as the second bispecific target in myeloma. | Multiple myeloma | none | bispecific, gprc5d | ||
C. Ola Landgren Chief of Myeloma and Director of the Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami · Sylvester Comprehensive Cancer Center, University of Miami Showed that MGUS precedes essentially all myeloma and leads MRD-driven trials aiming for cure without transplant. | Multiple myeloma | none | mrd, precursor | ||
Graham H. Jackson Professor of Clinical Haematology, Newcastle University; Consultant, Freeman Hospital · Newcastle Cancer Centre / Northern Centre for Cancer Care Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant. | Multiple myeloma | none | maintenance, uk | ||
Jesús G. Berdeja Director of Myeloma Research, Greco-Hainsworth Centers for Research, Tennessee Oncology; Sarah Cannon Research Institute · Tennessee Oncology / Greco-Hainsworth Centers for Research Led CARTITUDE-1, the trial that brought ciltacabtagene autoleucel, the most active myeloma CAR-T, to approval. | Multiple myeloma | none | car-t, community-research | ||
María-Victoria Mateos Consultant Hematologist and Director of the Myeloma Program, University Hospital of Salamanca · University Hospital of Salamanca / IBSAL Led ALCYONE and the smouldering myeloma trials that showed treating early can delay progression to active disease. | Multiple myeloma | none | smouldering, spain | ||
Meletios A. Dimopoulos Professor of Hematology and Medical Oncology, National and Kapodistrian University of Athens · National and Kapodistrian University of Athens, School of Medicine Greek haematologist who led POLLUX and CANDOR, two of the pivotal daratumumab combination trials in relapsed myeloma. | Multiple myeloma, Waldenström macroglobulinaemia | none | trialist, greece | ||
Michel Attal Haematologist and Director General, IUCT Oncopole, Toulouse · IUCT Oncopole (Institut Universitaire du Cancer de Toulouse) French haematologist whose trials established autologous stem-cell transplantation for myeloma in the 1990s and, in IFM 2009, showed that transplant still adds benefit in the era of lenalidomide, bortezomib and dexamethasone. | Newly diagnosed multiple myeloma, transplant-eligible, Multiple myeloma | none | transplant, trialist | ||
Nikhil C. Munshi Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Led KarMMa, which brought idecabtagene vicleucel, the first CAR-T for myeloma, to approval. | Multiple myeloma | none | car-t, genomics | ||
Noopur Raje Director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center · Massachusetts General Hospital Cancer Center Led the first-in-human trial of BCMA CAR-T (bb2121) in myeloma and studies of bone disease treatment. | Multiple myeloma | none | car-t, bone-disease | ||
Philippe Moreau Head of the Hematology Department, University Hospital Hôtel-Dieu, Nantes · Nantes University Hospital (CHU de Nantes) Led MajesTEC-1 and CASSIOPEIA, bringing the first bispecific antibody and daratumumab quadruplets to myeloma. | Multiple myeloma | none | bispecific, trialist | ||
Pieter Sonneveld Professor of Hematology, Erasmus MC Cancer Institute; Chair, European Myeloma Network · Erasmus MC Cancer Institute Led PERSEUS, which established daratumumab-VRd as the standard for transplant-eligible myeloma. | Multiple myeloma | none | transplant, hovon | ||
Sagar Lonial Chair of Hematology and Medical Oncology and Chief Medical Officer, Winship Cancer Institute of Emory University · Winship Cancer Institute of Emory University Led SIRIUS and the DREAMM programme, bringing daratumumab monotherapy and the BCMA ADC belantamab to myeloma. | Multiple myeloma | none | adc, swog | ||
Sigurdur Y. Kristinsson Professor of Hematology, University of Iceland; Landspitali University Hospital · Landspítali, the National University Hospital of Iceland Leads iStopMM, which screened most of Iceland's adults for myeloma precursors to test whether early detection helps. | Multiple myeloma | none | screening, epidemiology | ||
Thierry Facon Professor of Hematology, Lille University Hospital (CHU Lille) · Lille University Hospital (CHU de Lille) Led MAIA, which made daratumumab-lenalidomide-dexamethasone the standard for older patients with myeloma. | Multiple myeloma | none | older-patients, trialist |